Skip to content
BioCentury This Week cover art

All episodes

BioCentury This Week, 407 episodes. Page 3 of 5.

#
Title
201

Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors

202

Ep. 199 - China Summit Preview

203

Ep. 198 - Novartis Finds Focus & EU Pharma Law

204

Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview

205

Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi

206

Ep. 195 - East-West Summit Preview

207

Ep. 194 - IPO Outlook & IRA Lawsuits

208

Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC

209

Ep. 192 - Tier-jumpers: a Back to School Overview

210

Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits

211

Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial

212

Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital

213

Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations

214

Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC

215

Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis

216

Ep. 185 - Leqembi's Launch, Biotech IPOs, Sarepta Approval

217

Ep. 184 - Califf's FDA reforms & Polaris' Schulman

218

Ep. 183 - EMA's Cooke, What's Next for IPSCs, & Leerink is Back

219

Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO

220

Ep. 181 - Highlights from ASCO

221

Ep. 180 - ASCO, Neuropsych & the IRA

222

Ep. 179 - DMD Gene Therapies, CBER & NIH

223

Ep. 178 - Live from Bio€quity, Part 2

224

Ep. 177 - Live from Bio€quity, Part 1

225

Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success

226

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

227

Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal

228

Ep. 173 - EU VC Funds, Abortion Drug Ruling, IRA Insights

229

Ep. 172 - AACR Insights

230

Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology

231

Ep. 170 - Abortion Ruling & FDA; New VC Funds; IRA

232

Ep. 169 - FTC & Illumina, Plus: PCSK9s at SCOTUS

233

Ep. 168 - VCs' Take on SVB & New ALS Endpoint

234

Ep. 167 - The IRA, T Cell Therapies & The Distillery

235

Ep. 166 - SVB Shakeout: Next Steps for Biotech

236

Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen

237

Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech

238

Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure

239

Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up

240

Ep. 161 - New Cancer Paradigms, Distilling Innovations, & IPOs

241

Ep. 160 - Dose Optimization, Clinical Trials Diversity and QALYs

242

Ep. 159 - BIO's Priorities, ESG & Venture Trends

243

Ep. 158 - CAR T Manufacturing & Orphan Drugs

244

Ep. 157 - 2023 Markets Outlook & Buyside Picks

245

Ep. 156 - JPM Highlights & Alzheimer's Takeaways

246

Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends

247

Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery

248

Ep. 153 - The Inflation Reduction Act

249

Ep. 152 - Amgen's Horizon Takeout. Plus: ASH, SERDs

250

Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum

251

Ep. 150 - Model Term Sheets, Pragmatic Trials & Gene Therapy Prices

252

Ep. 149 - Takeaways from the East-West Summit

253

Ep. 148 - East-West Summit Highlights Part 2

254

Ep. 147 - East-West Summit Highlights Part 1

255

Ep. 146 - What's Next in Washington, Plus: SITC & the Distillery

256

Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK

257

Ep. 144 - Alnylam's IRA Pause, Plus Argenx & Accumulus

258

Ep. 143 - East-West Summit Preview

259

Ep. 142 - Lundbeck, Biogen, Biden & Biomanufacturing, Nora Volkow

260

Ep. 141 - Neoantigen Vaccines, Drug Pricing, U.S.-China & U.K. Turmoil

261

Ep. 140 - Turbulence at BIO, Plus 4Q Preview & the Distillery

262

Ep. 139 - Wins in Neurodegeneration, U.S.-China & Life Science Cares

263

Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen

264

Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order

265

Ep. 136 - IRA, KRAS & ESMO

266

Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders

267

Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline

268

Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent

269

Ep 135 Pt. 2 - CEOs in the Spotlight. Plus: Women Leaders, DEI

270

Ep 135 Pt. 1 - Back to School 2022 Overview

271

Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing

272

Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits

273

Ep. 132 - M&A & Data: recipe for a rebound?

274

Ep. 131 - Seagen, New Modalities & Structure

275

Ep. 130 - Steady as a Roche. Plus: Washington Turbulence

276

Ep. 129 - Burr Bill, Novartis Makeover, ALS Update

277

Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing

278

Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery

279

Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma

280

Ep. 125 - Next Steps for ARPA-H

281

Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery

282

Ep. 123 - Fixing FDA's Broken Advisory Panels

283

Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms

284

Ep. 121 - ASCO, CRISPR IP & CStone

285

Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal

286

Ep. 119 - Bio€quity Recap, Part 2

287

Ep. 118 - Bio€quity Recap, Part 1

288

Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap

289

Ep. 116 - The Road to Bio€quity 2022: Navigating Through Talent & Capital Headwinds

290

Ep. 115 - FDA Reform on Deck, Plus Translation at Howard

291

Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO

292

Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown

293

Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

294

Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom

295

Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation

296

Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA

297

Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com

298

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

299

Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H

300

Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia